AGIO Nov 2024 25.000 put
| Previous Close | 0.5500 |
| Open | 0.8600 |
| Bid | 0.0000 |
| Ask | 1.9500 |
| Strike | 25.00 |
| Expire Date | 2024-11-15 |
| Day's Range | 0.5500 - 0.8600 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 10 |
GuruFocus.comInsider Sale: CEO Brian Goff Sells Shares of Agios Pharmaceuticals Inc (AGIO)
On June 5, 2024, Brian Goff, Chief Executive Officer of Agios Pharmaceuticals Inc (NASDAQ:AGIO), executed a sale of 12,115 shares of the company.
GlobeNewswireUpdated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the time of the company’s presentation at the Goldman Sachs 45th Annual Global Healthcare Conference has been updated to Monday, June 10, 2024 at 8:40 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website a
ZacksAgios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study
Data from a late-stage study shows that transfusion-dependent thalassemia patients who received Agios' (AGIO) Pyrukynd demonstrated a statistically significant reduction in transfusion burden.
